Shenzhen Salubris Pharmaceuticals Co Ltd Cash Flow-to-Debt Ratio
Shenzhen Salubris Pharmaceuticals Co Ltd cash flow-to-debt ratio. Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has a Cash Flow-to-Debt Ratio of 0.20x as of September 2025, meaning its operating cash flow of CN¥400.70 Million could theoretically repay 0% of its total liabilities (CN¥2.05 Billion) in one year. Check Shenzhen Salubris Pharmaceuticals Co Ltd (002294) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
Cash flow-to-debt ratio of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024. Historical debt coverage capacity for Shenzhen Salubris Pharmaceuticals Co Ltd across 19 annual periods. Check earnings quality score of Shenzhen Salubris Pharmaceuticals Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Salubris Pharmaceuticals Co Ltd Cash Flow-to-Debt Ratio by Year (2006–2024)
Shenzhen Salubris Pharmaceuticals Co Ltd cash flow-to-debt ratio by year from 2006 to 2024. Year-by-year debt coverage analysis for Shenzhen Salubris Pharmaceuticals Co Ltd. For the full cash flow conversion analysis, see 002294 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.69x | CN¥1.19 Billion | CN¥1.71 Billion | ▲ +6.8% |
| 2023 | 0.65x | CN¥869.79 Million | CN¥1.34 Billion | ▲ +18.8% |
| 2022 | 0.55x | CN¥970.80 Million | CN¥1.78 Billion | ▼ -44.8% |
| 2021 | 0.99x | CN¥1.18 Billion | CN¥1.20 Billion | ▼ -4.5% |
| 2020 | 1.04x | CN¥1.37 Billion | CN¥1.33 Billion | ▼ -26.7% |
| 2019 | 1.41x | CN¥1.51 Billion | CN¥1.07 Billion | ▲ +8.9% |
| 2018 | 1.30x | CN¥1.34 Billion | CN¥1.03 Billion | ▼ -37.2% |
| 2017 | 2.07x | CN¥1.46 Billion | CN¥705.86 Million | ▲ +54.6% |
| 2016 | 1.34x | CN¥1.43 Billion | CN¥1.07 Billion | ▼ -12.6% |
| 2015 | 1.53x | CN¥1.06 Billion | CN¥691.25 Million | ▲ +28.8% |
| 2014 | 1.19x | CN¥982.25 Million | CN¥827.95 Million | ▼ -9.8% |
| 2013 | 1.32x | CN¥668.52 Million | CN¥508.36 Million | ▼ -5.6% |
| 2012 | 1.39x | CN¥521.21 Million | CN¥374.02 Million | ▲ +58.9% |
| 2011 | 0.88x | CN¥272.32 Million | CN¥310.52 Million | ▲ +45.4% |
| 2010 | 0.60x | CN¥186.65 Million | CN¥309.50 Million | ▼ -33.3% |
| 2009 | 0.90x | CN¥134.28 Million | CN¥148.59 Million | ▲ +69.0% |
| 2008 | 0.53x | CN¥77.89 Million | CN¥145.70 Million | ▲ +11.5% |
| 2007 | 0.48x | CN¥52.75 Million | CN¥109.98 Million | ▲ +108.5% |
| 2006 | 0.23x | CN¥12.00 Million | CN¥52.19 Million | — |